Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings plc, a developer of novel immunotherapies, is set to present compelling data from its Phase 2 SCOPE trial at the ASCO Annual Meeting in Chicago. The trial’s results for the cancer vaccine SCIB1, used in advanced melanoma treatment, show an impressive 85% objective response rate when combined with checkpoint inhibitors. This marks a significant milestone for the company, highlighting their advancements in the cancer vaccine field.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
